- Traditional methods for evaluating therapeutic efficacy and cardiotoxicity often lead to high failure rates during clinical trials, resulting in significant development costs
- Human-specific diseases cannot be accurately modeled by animals, leading to limited medical options or advancements
- This new study leverages the capabilities of artificial intelligence (AI) and machine learning (ML) to address the challenge of achieving automated and comprehensive "smart" drug screening using Medera's mini-Heart technology platform
- Innovative AI/ML-based model combines data from multiple human mini-Heart screening assays and takes advantage of the complementary strengths to achieve superior next-generation drug classification capabilities
- The unique combination of AI/ML and human mini-Hearts can accelerate drug discovery, clinical translation and precision medicine by improving screening efficiency, reducing costs, enhancing safety and creating new opportunities for patient benefits
SUMMIT, N.J. and BOSTON, Mass., Oct. 31, 2024 /PRNewswire/ -- Medera Inc. ("Medera"), a clinical-stage biotechnology company focused on targeting difficult-to-treat cardiovascular diseases using a range of next-generation gene- and cell-based approaches, announced today the publication of a new study in the peer-reviewed journal Pharmacological Research (volume 209). This study, entitled "Enhanced Drug Classification Using Machine Learning with Multiplexed Cardiac Contractility Assays," demonstrates how Novoheart, Medera's wholly-owned preclinical subsidiary focused on human cardiovascular disease modeling for drug discovery, is leveraging AI and ML to improve next-generation drug screening processes.
